Related Experiment Video
Updated: May 31, 2026

A Reference Broth Microdilution Method for Dalbavancin In Vitro Susceptibility Testing of Bacteria that Grow Aerobically
Published on: September 9, 2015
Vancomycin-resistant enterococcal bacteraemia and daptomycin: are higher doses necessary?
Esther A King1, Dorothy McCoy, Samit Desai
1Department of Pharmacy, Hackensack University Medical Center, Hackensack, NJ, USA. esther.aizenberg@gmail.com
Background:
The MIC corresponding to daptomycin susceptibility for vancomycin-resistant enterococci (VRE) is ≤ 4 mg/L. Based on the concentration-dependent killing properties of daptomycin, there may be concern about achieving adequate concentrations when the MIC approaches the upper end of the susceptible range (3-4 mg/L). Higher doses of daptomycin may be needed to treat VRE isolates with higher MICs.
Methods:
We conducted a single-centre retrospective chart review of adult cases with VRE bacteraemia who received daptomycin as initial therapy. The primary outcome was time to microbiological cure (TMC) between standard doses (≤ 6 mg/kg) and high doses (> 6 mg/kg) of daptomycin and whether TMC differed based on MICs. The secondary outcome evaluated the daptomycin MIC distribution and assessed whether recent exposure to vancomycin was associated with higher daptomycin MICs.
Results:
Forty-six cases were included in the primary analysis and 60.9% of patients were neutropenic. The two dose groups differed in the baseline characteristics of age, body mass index, blood culture source and catheter removal. Median TMC was 2 days for both dose groups. There was no significant difference in TMC between MIC subgroups of ≤ 2 mg/L versus >2 and ≤ 4 mg/L. For the secondary analysis 227 VRE isolates were evaluated and 62% had daptomycin MICs of 3-4 mg/L. Each daptomycin MIC group had a similar incidence of prior vancomycin exposure.
Conclusions:
Based on this retrospective review we did not observe a difference in TMC based on daptomycin dose and MIC; however, there were various limitations to this study, and the study was not powered to detect a difference in TMC. Also, prior vancomycin exposure did not appear to influence daptomycin MICs. The frequency of daptomycin MICs of 3-4 mg/L reported in this study is higher than those reported in the literature.
Insights
This study found no difference in microbiological cure time for vancomycin-resistant enterococci (VRE) treated with standard or high-dose daptomycin, regardless of minimum inhibitory concentration (MIC). Prior vancomycin exposure did not affect daptomycin MICs.
Area of Science:
- Infectious Diseases
- Pharmacology
- Clinical Microbiology
Background:
- Vancomycin-resistant enterococci (VRE) infections pose a significant challenge, with daptomycin susceptibility defined by a minimum inhibitory concentration (MIC) of ≤ 4 mg/L.
- Daptomycin's concentration-dependent killing necessitates adequate drug exposure, raising concerns for VRE isolates with MICs nearing the susceptible threshold (3-4 mg/L).
- Higher daptomycin doses may be considered for VRE with elevated MICs.
Purpose of the Study:
- To compare time to microbiological cure (TMC) in adult VRE bacteremia patients receiving standard (≤ 6 mg/kg) versus high (> 6 mg/kg) daptomycin doses.
- To determine if TMC varied based on daptomycin MIC values.
- To evaluate daptomycin MIC distribution and the association between prior vancomycin exposure and higher daptomycin MICs.
Main Methods:
- A single-center retrospective chart review of adult VRE bacteremia cases treated with daptomycin as initial therapy.
- Primary outcome: TMC comparison between standard and high daptomycin dose groups, stratified by MIC.
- Secondary outcomes: Daptomycin MIC distribution analysis and assessment of prior vancomycin exposure's impact on MICs.
Main Results:
- Forty-six patients were included in the primary analysis; 60.9% were neutropenic.
- Median TMC was 2 days for both standard and high daptomycin dose groups, with no significant difference between MIC subgroups (≤ 2 mg/L vs. >2 and ≤ 4 mg/L).
- In the secondary analysis of 227 VRE isolates, 62% had daptomycin MICs of 3-4 mg/L, with similar prior vancomycin exposure across MIC groups.
Conclusions:
- This retrospective review did not demonstrate a difference in TMC based on daptomycin dose or MIC for VRE bacteremia.
- The study was not powered to detect differences in TMC, and limitations exist.
- Prior vancomycin exposure did not appear to influence daptomycin MICs, and the observed frequency of higher MICs (3-4 mg/L) exceeds previously reported literature values.
Related Concept Videos
Estimation of k and VD of Aminoglycosides
Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations
Clinical Significance of Antibiotic Resistance
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Acute Pyelonephritis II: Diagnostic Studies and Management
Dosage Interval and Administration Route: Determination Methods